Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 29325634.
- Also identified by DOI 10.1016/j.jacc.2017.10.085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When assessing ischemic stroke risk in patients with atrial fibrillation (AF), the CHA<sub>2</sub>DS<sub>2</sub>-VASc score is calculated based on the baseline risk factors, and the outcomes are determined after a follow-up period. However, the stroke risk in patients with AF does not remain static, and with time, patients get older and accumulate more comorbidities. This study hypothesized that the "Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc score," which reflects the change in score between baseline and follow-up, would be more predictive of ischemic stroke compared with the baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score. A total of 31,039 patients with AF who did not receive antiplatelet agents or oral anticoagulants, and who did not have comorbidities of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score except for age and sex, were studied. The Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were defined as the differences between the baseline and follow-up CHA<sub>2</sub>DS<sub>2</sub>-VASc scores. During 171,956 person-years, 4,103 patients experienced ischemic stroke. The accuracies of baseline, follow-up, and Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc scores in predicting ischemic stroke were analyzed and compared. The mean baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 1.29, which increased to 2.31 during the follow-up, with a mean Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1.02. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score remained unchanged in only 40.8% of patients. Among 4,103 patients who experienced ischemic stroke, 89.4% had a Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥1 compared with only 54.6% in patients without ischemic stroke, and 2,643 (64.4%) patients had ≥1 new-onset comorbidity, the most common being hypertension. The Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc score was a significant predictor of ischemic stroke that performed better than baseline or follow-up CHA<sub>2</sub>DS<sub>2</sub>-VASc scores, as assessed by the C-index and the net reclassification index. In this AF cohort, the authors demonstrated that the CHA<sub>2</sub>DS<sub>2</sub>-VASc score was not static, and that most patients with AF developed ≥1 new stroke risk factor before presentation with ischemic stroke. The Delta CHA<sub>2</sub>DS<sub>2</sub>-VASc score, reflecting the change in score between baseline and follow-up, was strongly predictive of ischemic stroke, reflecting how stroke risk in AF is a dynamic process due to increasing age and incident comorbidities.
Medical subject headings
- Anticoagulants
- Atrial Fibrillation
- Brain Ischemia
- Hypertension
- Platelet Aggregation Inhibitors
- Stroke